Price
62.75
+1.04%52W Range
Market Cap
₹132.03 Cr
Traded: ₹0.04 Cr (0.03%) 0.0x
Free Float: ₹55.95 Cr (0.07% of FF traded)
Volume · 60D trend
6.63 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +7.0% | +10.0% | +11.0% | -- | -- | Accelerating |
| Sales | +7.0% | +2.0% | +4.0% | -- | +0.0% | Stable |
| Profit | +8.0% | +24.0% | +6.0% | -- | -85.0% | Decelerating |
| Return | +7.0% | +4.0% | -4.0% | -30.0% | -- | Decelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 31 | 29 | 26 | 19 | 40 | 26 | 25 | 21 | 24 | 27 | 32 | 25 | 29 | 27 | 14 |
| Expenses | 28 | 28 | 28 | 29 | 19 | 40 | 25 | 22 | 21 | 20 | 25 | 29 | 27 | 20 | 25 | 19 |
| Operating Profit | -4 | 4 | 2 | -2 | 0 | 0 | 1 | 3 | 1 | 4 | 2 | 3 | -1 | 9 | 3 | -6 |
| OPM % | -16.6% | 11.5% | 5.2% | -8.6% | 2.3% | 0.5% | 2.8% | 13.3% | 2.5% | 14.9% | 8.9% | 10.3% | -4.5% | 31.6% | 9.6% | -42.0% |
| Other Income | 6 | -0 | 1 | 3 | 12 | 2 | 9 | 7 | 5 | 4 | 4 | 3 | 4 | -1 | 3 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 1 | 3 | 2 | 0 | 12 | 2 | 9 | 10 | 5 | 7 | 5 | 6 | 3 | 8 | 5 | 0 |
| Tax % | 0.0% | 55.0% | 9.2% | 0.0% | 0.0% | 201.9% | 0.0% | 20.3% | 0.0% | 46.7% | 14.9% | 0.0% | 0.0% | 41.6% | 0.0% | 0.0% |
| Net Profit | 1 | 1 | 2 | 0 | 12 | -2 | 9 | 8 | 5 | 4 | 5 | 6 | 3 | 5 | 5 | 0 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 0.5 | 0.7 | 0.8 | 0.1 | 5.6 | -1.0 | 4.2 | 3.6 | 2.4 | 1.7 | 2.1 | 2.8 | 1.4 | 2.2 | 2.4 | 0.1 |
| Sales Growth (YoY) | 25.2% | -21.3% | 11.1% | 5.3% | -10.9% | 69.1% | -4.3% | -23.0% | -15.7% | -19.0% | 0.0% | 139.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -23.8% | 8.1% | 10.6% | 37.4% | -52.1% | 52.7% | 4.8% | 16.3% | -9.2% | -13.6% | -15.7% | 27.4% | -12.8% | 6.8% | 101.7% | -- |
| OP Growth (YoY) | -1020.9% | 1700.0% | 104.1% | -167.8% | -18.9% | -94.3% | -69.5% | -0.9% | 146.5% | -61.9% | -7.3% | 158.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | -210.0% | 138.4% | 167.1% | -623.3% | 115.0% | -73.0% | -77.7% | 526.4% | -84.9% | 44.4% | -27.5% | 393.9% | -112.4% | 251.9% | 146.0% | -- |
| Profit Growth (YoY) | -92.0% | 165.0% | -82.0% | -99.0% | 131.0% | -160.0% | 98.0% | 33.0% | 70.0% | -24.0% | -12.0% | 2795.0% | 11.0% | 233.0% | -5.0% | -96.0% |
| EPS Growth (YoY) | -91.6% | 165.3% | -82.0% | -98.6% | 131.0% | -159.8% | 97.7% | 32.7% | 68.1% | -23.5% | -11.9% | 2650.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -28.8% | -13.2% | 1420.0% | -99.1% | 653.5% | -123.9% | 15.9% | 50.8% | 43.2% | -21.0% | -22.2% | 91.0% | -34.8% | -9.1% | 2330.0% | -- |
| OP Margin | -16.6% | 11.5% | 5.2% | -8.6% | 2.3% | 0.5% | 2.8% | 13.3% | 2.5% | 14.9% | 8.9% | 10.3% | -4.5% | 31.6% | 9.6% | -42.0% |
| Net Margin | 4.1% | 4.4% | 5.5% | 0.4% | 61.6% | -5.3% | 34.0% | 30.8% | 23.8% | 15.0% | 16.5% | 17.9% | 11.9% | 15.9% | 18.8% | 1.5% |
| Material Cost % | 76.0% | 51.0% | 67.0% | 76.0% | 58.0% | 69.0% | 55.0% | 57.0% | 64.0% | 45.0% | 60.0% | 64.0% | 80.0% | 43.0% | 63.0% | 94.0% |
| Employee Cost % | 16.0% | 16.0% | 13.0% | 14.0% | 18.0% | 11.0% | 13.0% | 14.0% | 15.0% | 16.0% | 12.0% | 10.0% | 12.0% | 13.0% | 11.0% | 21.0% |
| P/S | 1.19 | 1.31 | 1.31 | 1.25 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 32.35 | 9.33 | 12.92 | 7.45 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.71 | 0.74 | 0.82 | 0.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Results for the quarter ended June 2026 along with the approval of Notice of 38th Annual General Meeting
CLARIFICATION ON BOARD MEETING DATE WITH RESPECT TO THE EARLIER SUBMISSION
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. The Standalone and Consolidated ....
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 , we hereby inform you that Ms. Jyoti Jain has ceased to be an ....
Ms.Yashoda Patidar has resigned from the post of Company Secretary & Complaince Officer w.e.f. 26th July 2026.
We wish to inform that in pursuant of Securities and Exchange Board of India (Prohibition of Insider Trading)(Amendment) Regulation 2018,and Company''s Code of Conduct for Regulating, Monitoring ....
Results for the quarter and year ended March,2026
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Standalone & Consolidated ....
Appointment of Ms.Yashoda Patidar as the Company Secretary and Complaince Officer of the company w.e.f. April 11,2026.
Clarification on the Price Sensitive Information via email dt8th April,2026
The Exchange has sought clarification from Alpa Laboratories Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
The trading Window of the company shall remain closed w.e.f, 01st April 2026 till 48 hours after the declaration of the Financial results by the company for the fourth quarter and financial ....
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vinit Shah
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vinit Shah
Ms Srashti Chopra has resigned from the post of Company Secreatary and Compliance Officer wef 25th March 2026.
Financial Results
Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve the Unaudited Financial results ....
Alpa Laboratories has informed the exchange regarding the closure of trading window pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015
Financial Results for the quarter and half year ended September 30,2025
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve ALPA LABORATORIES LIMITED ....
,Alpa Laboratories Limited has submitted the exchange a copy of Scrutinizer''s Report of AGM held on September 29, 2025.
Alpa Laboratories has informed the exchange regarding outcome of Annual General Meeting held on September 29, 2025.
Alpa Laboratories has informed the exchange regarding the Closure of Trading Window pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015
Alpa Laboratories Limited has informed the exchange that Register of Members and Share Transfer Books of the Company will remain closed from 22-sep 2025 to 29-Sep 2025 for the Purpose of ....
Annual Report along with notice of AGM for the year ended March,2025.
Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve The Standalone and Consolidated ....
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Alpa Laboratories Limited has informed the exchange about closure of Trading Window
Submission of Annual Secretarial Compliance report for the Financial Year ended 31 March, 2025.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pravin Shah
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shitul Shah
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shitul Shah
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shitul Shah
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shitul Shah
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pravin Shah
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mahendra Singh Chawla
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Paresh Chawla
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Paresh Chawla
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to consider and approve To consider and approve the ....
The Trading Window shall remain closed with effect from 1st April, 2025 till 48 hours after the declaration of Financial Results of the Company for the fourth quarter and financial year ....
Clarification on the format prescribed by SEBI for the Financial Results.
Integrated Filing (Financial) for the Quarter and nine months ended December 31, 2024
Change in designation of Mr. Vitthal Kothana (DIN- 09489318) from Non-Executive Director to Executive Director.
Appointment of MS. Srashti Chopra as a company secretary and compliance officer
Annual Reports
15